酪氨酸激酶抑制剂治疗中国甲状腺癌患者的研究进展

Progress of tyrosine kinase inhibitors in treatment of Chinese patients with thyroid cancer

晚期甲状腺癌患者因传统治疗手段效果欠佳而预后不良,酪氨酸激酶抑制剂(TKI)主要通过阻断细胞信号转导来抑制肿瘤的生长和增殖,为其提供了新的治疗选择。现今,部分TKI类药物如索拉非尼、仑伐替尼和安罗替尼已被国家药品监督管理局批准用于治疗晚期甲状腺癌。此外,阿帕替尼、多纳非尼、索凡替尼等也在我国相继开展了临床试验,结果显示三者均能有效控制晚期甲状腺癌患者病情、延长无进展生存期,且安全性较好。

The prognosis of patients with advanced thyroid cancer is poor because of the ineffectiveness of traditional treatment.Tyrosine kinase inhibitors(TKI),which inhibit tumor growth and proliferation mainly by blocking cellular signal transduction,provide a new therapeutic option for them.Nowadays,some TKI such as sorafenib,lenvatinib and anlotinib have been approved by the National Medical Products Administration(NMPA)for the treatment of advanced thyroid cancer.In addition,clinical trials of apatinib,donafenib and surufatinib have also been carried out in China,and the results have showed that all three can effectively control the condition of patients with advanced thyroid cancer,prolong progression free survival and have good safety.